Biotech Botanix Pharmaceuticals has raised $7.4 million in a placement of new shares to help it fund the further development of its dermatology products that contain a synthetic form of the cannabis compound, cannabidiol.
Biotech Botanix Pharmaceuticals has raised $7.4 million in a placement of new shares to help it fund the further development of its dermatology products that contain a synthetic form of the cannabis compound, cannabidiol.